Omnicell (OMCL) Aktienübersicht
Omnicell, Inc. bietet zusammen mit seinen Tochtergesellschaften Gesundheitstechnologie in den Vereinigten Staaten und international an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für OMCL festgestellt.
OMCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omnicell, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$45.59 |
| 52-Wochen-Hoch | US$55.00 |
| 52-Wochen-Tief | US$26.85 |
| Beta | 0.97 |
| 1 Monat Veränderung | 12.04% |
| 3 Monate Veränderung | 32.53% |
| 1 Jahr Veränderung | 53.14% |
| 3 Jahre Veränderung | -37.87% |
| 5 Jahre Veränderung | -69.79% |
| Veränderung seit IPO | 379.39% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jul 06
OMCL: Cabinet Replacement Cycle Will Support Higher Multiple As New Leadership Executes
Omnicell's updated analyst price target has increased from $63 to $70. Analysts cited adjusted fair value, refined discount rate assumptions, and expectations for a higher future P/E multiple to support the change.
Narrativ-Update • Jun 22
OMCL: Earnings Rebound And Guidance Will Support Higher Future Earnings Multiple
Analysts have nudged their price targets on Omnicell higher, with recent Street research pointing to modestly improved expectations that support a slightly richer long term fair value framework anchored around $55. Analyst Commentary Recent Street research on Omnicell reflects a mixed tone, with higher price targets framed within a cautious backdrop.Analyseartikel • Jun 21
Omnicell (OMCL) Stock Could Be 36.3% Undervalued After Specialty Pharmacy Leadership Hire
Omnicell (OMCL) stock is back in focus after the company appointed veteran pharmacy operator Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, a move tied directly to its Specialty Pharmacy and 340B ambitions. See our latest analysis for Omnicell. Omnicell’s latest leadership change comes after a mixed stretch in the market, with the stock’s share price showing a 13.82% 90 day return but down 12.07% over 30 days, while the 1 year total shareholder return...Recent updates
Narrativ-Update • Jul 06
OMCL: Cabinet Replacement Cycle Will Support Higher Multiple As New Leadership Executes
Omnicell's updated analyst price target has increased from $63 to $70. Analysts cited adjusted fair value, refined discount rate assumptions, and expectations for a higher future P/E multiple to support the change.Narrativ-Update • Jun 22
OMCL: Earnings Rebound And Guidance Will Support Higher Future Earnings Multiple
Analysts have nudged their price targets on Omnicell higher, with recent Street research pointing to modestly improved expectations that support a slightly richer long term fair value framework anchored around $55. Analyst Commentary Recent Street research on Omnicell reflects a mixed tone, with higher price targets framed within a cautious backdrop.Analyseartikel • Jun 21
Omnicell (OMCL) Stock Could Be 36.3% Undervalued After Specialty Pharmacy Leadership Hire
Omnicell (OMCL) stock is back in focus after the company appointed veteran pharmacy operator Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, a move tied directly to its Specialty Pharmacy and 340B ambitions. See our latest analysis for Omnicell. Omnicell’s latest leadership change comes after a mixed stretch in the market, with the stock’s share price showing a 13.82% 90 day return but down 12.07% over 30 days, while the 1 year total shareholder return...
Narrativ-Update • Jun 04
OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Demand
Analysts have lifted their price target on Omnicell by $12 in total, supported by refreshed assumptions on discount rate, revenue growth, profit margin and future P/E. These changes leave the stock's fair value estimate broadly unchanged at about $61.29.Narrativ-Update • May 19
OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Upside
Analysts lifted the Omnicell price target by about $4, reflecting updated fair value estimates and revised assumptions on discount rate, revenue growth, profit margin, and future P/E multiples, supported by recent research from multiple firms. Analyst Commentary Recent Street research includes price target increases of about $2 and $10, which gives a sense of how bullish and cautious views are being weighed around Omnicell right now.Analyseartikel • May 14
Omnicell's (NASDAQ:OMCL) Conservative Accounting Might Explain Soft Earnings
The market was pleased with the recent earnings report from Omnicell, Inc. ( NASDAQ:OMCL ), despite the profit numbers...Narrativ-Update • May 01
OMCL: New Product Cycle Will Reset Expectations And Support Higher Future Earnings Multiple
Analysts have reset their view on Omnicell, with the consolidated fair value estimate moving from $49.00 to $55.00. This reflects updated assumptions on discount rate, growth, margins and future P/E, alongside recent price target hikes and rating changes across the Street.Narrativ-Update • Apr 16
OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle
Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.Narrativ-Update • Apr 01
OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing
Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.Narrativ-Update • Mar 18
OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing
Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.Narrativ-Update • Mar 04
OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside
Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.Narrativ-Update • Feb 18
OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside
Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.Analyseartikel • Feb 12
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
The Omnicell, Inc. ( NASDAQ:OMCL ) share price has softened a substantial 26% over the previous 30 days, handing back...Narrativ-Update • Feb 04
OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market
Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.Narrativ-Update • Jan 21
OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance
Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.Narrativ-Update • Jan 06
OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile
Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.Narrativ-Update • Dec 18
OMCL: New Medication Management Platform Will Support Future Upside Potential
Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.Narrativ-Update • Dec 04
OMCL: Share Repurchases Will Support Future Upside Potential
Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).Narrativ-Update • Nov 20
OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside
Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.Analyseartikel • Nov 13
Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified
Omnicell, Inc. ( NASDAQ:OMCL ) shareholders would be excited to see that the share price has had a great month, posting...Narrativ-Update • Nov 06
OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position
Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.Seeking Alpha • Jul 31
Omnicell Q2 Earnings: Market Ignoring The Segments
Summary Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% upside, with Wall Street consensus trailing behind. The primary risk is the pace of transition from product to service revenue, but a strong backlog mitigates margin and cash flow concerns. Given robust service growth and healthy backlog, I maintain Omnicell at strong buy, seeing current volatility as a long-term buying opportunity. Read the full article on Seeking AlphaAnalyseartikel • Jul 16
Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Analyseartikel • Jun 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Omnicell fair value estimate is US$40.16 Omnicell is estimated...Neues Narrativ • May 27
Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.Analyseartikel • May 14
It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights Omnicell's Annual General Meeting to take place on 21st of May CEO Randy Lipps' total compensation...Analyseartikel • May 09
US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results
There's been a notable change in appetite for Omnicell, Inc. ( NASDAQ:OMCL ) shares in the week since its first-quarter...Analyseartikel • Apr 07
Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Mar 20
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it received a lot of attention from a...Analyseartikel • Feb 14
Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Despite posting healthy earnings, Omnicell, Inc.'s ( NASDAQ:OMCL ) stock has been quite weak. Our analysis suggests...Seeking Alpha • Feb 12
Omnicell Q4 Earnings: Ignore The Short-Term Noise
Summary Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and improving margins, indicating long-term value. Downside risks include the need to balance service growth with product decline, but the healthy backlog mitigates these concerns, presenting a buying opportunity. Read the full article on Seeking AlphaAnalyseartikel • Feb 09
Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a mediocre week for Omnicell, Inc. ( NASDAQ:OMCL ) shareholders, with the stock dropping 11% to US$40.16 in...Analyseartikel • Jan 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Key Insights Omnicell's estimated fair value is US$59.79 based on 2 Stage Free Cash Flow to Equity Omnicell's US$44.35...Aktionärsrenditen
| OMCL | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 5.9% | -1.5% | 0.6% |
| 1Y | 53.1% | -19.9% | 19.5% |
Rendite im Vergleich zur Industrie: OMCL übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -19.9 erzielte.
Rendite vs. Markt: OMCL übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19.5 erzielte.
Preisvolatilität
| OMCL volatility | |
|---|---|
| OMCL Average Weekly Movement | 8.0% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: OMCL hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: OMCLDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1992 | 3,525 | Randy Lipps | www.omnicell.com |
Omnicell, Inc. bietet zusammen mit seinen Tochtergesellschaften Gesundheitstechnologie in den Vereinigten Staaten und international an. Das Unternehmen bietet Lösungen für Krankenhäuser und Gesundheitssysteme an, wie z. B. Points of Care für die Arbeitsabläufe der Kliniker in den Patientenversorgungsbereichen des Gesundheitswesens, Titan XT, ein automatisiertes Abgabesystem, XTExtend, ein Konsolentausch für seine XT-Schränke, und Central Pharmacy Dispensing Service für den Medikamentenabgabeprozess. Darüber hinaus bietet das Unternehmen den Central Med Automation Service für die Medikamentenabgabe, den IV Compounding Service, ein hausinternes Compounding-System, Spezialapothekendienste, einschließlich einer schlüsselfertigen Lösung zur Unterstützung von Gesundheitssystemen bei der Einrichtung, Verwaltung und Optimierung einer unternehmenseigenen Spezialapotheke, die EnlivenHealth-Plattform zur digitalen Unterstützung von Einzelhandels- und Gemeindeapotheken, Lösungen zur Einhaltung von Medikamenten, die Verbrauchsmaterialien und Medikamentenverpackungssysteme umfassen, sowie Technologieimplementierung, Kundenschulung und -training, Programmmanagement und damit verbundene Angebote für professionelle Dienstleistungen.
Omnicell, Inc.'s Grundlagenzusammenfassung
| OMCL grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.05b |
| Gewinn(TTM) | US$20.43m |
| Umsatz(TTM) | US$1.23b |
101.5x
Kurs-Gewinn-Verhältnis 1.7x
Kurs-Umsatz-VerhältnisIst OMCL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| OMCL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.23b |
| Kosten der Einnahmen | US$687.59m |
| Bruttogewinn | US$537.47m |
| Sonstige Ausgaben | US$517.04m |
| Gewinn | US$20.43m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.45 |
| Bruttomarge | 43.87% |
| Nettogewinnspanne | 1.67% |
| Schulden/Eigenkapital-Verhältnis | 13.4% |
Wie hat sich OMCL auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/09 10:12 |
| Aktienkurs zum Tagesende | 2026/07/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Omnicell, Inc. wird von 19 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Raymond Myers | Benchmark Company |
| William Sutherland | Benchmark Company |
| Zhilin Long | Berenberg |